The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | ctDNA and HRD analysis of a Phase II trial of atezolizumab combo in recurrent ovarian cancer
Jeesun Yoon, MD, from Seoul National University in South Korea, discussed the findings of a Phase II trial (NCT04727996) investigating the efficacy and safety of atezolizumab in combination with bevacizumab and chemotherapy for recurrent ovarian cancer in patients unsuitable for platinum therapy. Among the 35 patients with baseline ctDNA NGS data, eight exhibited homologous recombination deficiency (HRD). Similar trends were observed in tissue NGS and ctDNA NGS, though not identical. Dr Yoon highlighted the challenges in obtaining tumor tissue biopsies, especially in biliary tract cancer like extrahepatic cholangiocarcinoma, prompting the use of ctDNA for patient selection. The study also noted changes in ctDNA levels correlating with treatment response, emphasizing the importance of monitoring early response through ctDNA levels. This interview occurred during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
